FDA approves Adcetris (brentuximab vedotin) combination regimen for the treatment of relapsed/refractory diffuse large B-cell lymphoma – Pfizer
Pfizer Inc. announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the… read more.
